
An interim Phase 3 analysis found a 58% lower risk of metastasis or death when darolutamide was added to standard treatment.
Orion said an interim Phase 3 analysis found that darolutamide, added to androgen deprivation therapy (ADT) and radiation, reduced the risk of metastasis or death by 58% in prostate cancer patients at high risk of recurrence. The results will be presented at the European Society for Medical Oncology Congress.
After a median follow-up of 3.8 years, four-year metastasis-free survival was 95% among patients receiving darolutamide, compared with 88% for those given placebo. The trial’s secondary results included a 53% reduction in the risk of prostate-specific antigen progression, according to Orion.
Grade 3 or higher adverse events occurred in 43% of patients receiving darolutamide and 36% in the placebo group. Darolutamide is not approved for this treatment setting, and follow-up is continuing to assess longer-term outcomes, including overall survival.
This article was produced with the help of AI technology. Based on reporting by the outlets listed above.